XML 46 R26.htm IDEA: XBRL DOCUMENT
v3.24.1

Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses - EUR (€) | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items] |  |  |
Research and development expenses | € 41,024,131 | € 37,526,090 | € 35,697,935
Third-party services [Member] |  |  |
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items] |  |  |
Research and development expenses | 31,802,983 | 28,543,503 | 28,247,081
Clinical material and related manufacturing services [Member] |  |  |
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items] |  |  |
Research and development expenses | 18,109,345 | 16,194,152 | 6,615,840
Clinical, pre-clinical studies [Member] |  |  |
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items] |  |  |
Research and development expenses | 13,693,638 | 12,349,351 | 21,631,240
Employee benefits expenses [Member] |  |  |
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items] |  |  |
Research and development expenses | 6,776,853 | 6,957,866 | 5,941,813
Equity-settled share-based payment expense [Member] |  |  |
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items] |  |  |
Research and development expenses | 1,500,670 | 2,456,571 | 1,622,898
Legal and consulting fees [Member] |  |  |
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items] |  |  |
Research and development expenses | 1,758,283 | 1,690,448 | 1,074,710
Other expenses [Member] |  |  |
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items] |  |  |
Research and development expenses | € 686,012 | € 334,273 | € 434,331

X
- Definition The amount of expenditure directly attributable to research or development activities, recognised in profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 126 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ResearchAndDevelopmentExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems
Namespace Prefix: | ifrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=ifrx_ThirdpartyServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=ifrx_ManufacturingOfClinicalMaterialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=ifrx_clinicalPreclinicalStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |